It was an auspicious moment to start a conference. Deborah Harland, partner of SR One, announced at the start of the UK BioTrinity conference on 13 April 2011, that the corporate venture arm of GlaxoSmithKline Plc, had just led a €15 million fundraising for the Austrian antibody company, F-Star GmbH.
